Juniper Pharmaceuticals, Inc.

Juniper Pharmaceuticals (Nasdaq: JNP) is focused on developing therapeutics that address unmet medical needs in women's health. Juniper is accelerating development of its proprietary product pipeline, leveraging in-house formulation, pharmaceutical development, and manufacturing. R&D is substantially funded by cash flow generated by the CRINONE franchise and the contract pharmaceutical services provided by Juniper Pharma Services. Pipeline products utilize Juniper’s novel drug delivery technologies, including a segmented intravaginal ring (IVR) developed in the laboratories of Dr. Robert Langer at MIT and Dr. William Crowley at Mass. General Hospital. The Company is advancing IVR candidates for overactive bladder in women, HRT for symptoms of menopause, and prevention of preterm birth in women with a short cervical length.Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S..